drugset / Trial / NCT00730223
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
Non-randomizedCrossoverOpen-labelHealth-services research
Summary
To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug levels and central nervous system side affects in people who take nevirapine or efavirenz.
Timeline
- Start
- 2004-03
- Primary completion
- 2006-03
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Nevirapine | Small molecule | 200 mg | Oral |